Stewardship Approach for Optimizing Antimicrobial Therapy through Use of a Rapid Microarray Assay on Blood Cultures Positive for Enterococcus Species

被引:72
作者
Sango, Aaron [1 ]
McCarter, Yvette S. [2 ]
Johnson, Donald [1 ]
Ferreira, Jason [1 ]
Guzman, Nilmarie [3 ]
Jankowski, Christopher A. [1 ]
机构
[1] Univ Florida Hlth Jacksonville, Dept Pharm, Jacksonville, FL USA
[2] Univ Florida Hlth Jacksonville, Dept Pathol & Lab Med, Jacksonville, FL 32610 USA
[3] Univ Florida Hlth Jacksonville, Div Infect Dis, Dept Med, Jacksonville, FL USA
关键词
INFECTIOUS-DISEASES-SOCIETY; VANCOMYCIN-RESISTANT; MANAGEMENT; BACTEREMIA; DIAGNOSIS; UPDATE; IMPACT;
D O I
10.1128/JCM.01951-13
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Enterococci are a major cause of bloodstream infections in hospitalized patients and have limited antimicrobial treatment options due to their many resistance mechanisms. Molecular technologies have significantly shortened the time to enterococcal isolate identification compared with conventional methods. We evaluated the impact of rapid organism identification and resistance detection with the Verigene Gram-positive blood culture microarray assay on clinical and economic outcomes for patients with enterococcal bacteremia. A single-center preintervention/postintervention quasiexperimental study compared inpatients with enterococcal bacteremia from 1 February 2012 to 9 September 2012 (preintervention period) and 10 September 2012 to 28 February 2013 (postintervention period). An infectious disease and/or critical care pharmacist was contacted with the microarray assay results, and effective antibiotics were recommended. The clinical and economic outcomes for 74 patients were assessed. The mean time to appropriate antimicrobial therapy was 23.4 h longer in the preintervention group than in the postintervention group (P = 0.0054). A nonsignificant decrease in the mean time to appropriate antimicrobial therapy was seen for patients infected with vancomycin-susceptible Enterococcus isolates (P = 0.1145). For patients with vancomycin-resistant Enterococcus bacteremia, the mean time to appropriate antimicrobial therapy was 31.1 h longer in the preintervention group than in the postintervention group (P < 0.0001). In the postintervention group, the hospital length of stay was significantly 21.7 days shorter (P = 0.0484) and mean hospital costs were $60,729 lower (P = 0.02) than in the preintervention group. The rates of attributed deaths in the two groups were not statistically different. Microarray technology, supported by pharmacy and microbiology departments, can decrease the time to appropriate antimicrobial therapy, the hospital length of stay, and health care costs.
引用
收藏
页码:4008 / 4011
页数:4
相关论文
共 12 条
  • [1] Baddour LM, 2005, CIRCULATION, V111, pE394, DOI 10.1161/CIRCULATIONAHA.105.165564
  • [2] Bartlett JG., 2012, J HOPKINS ABX GUIDE
  • [3] An Antimicrobial Stewardship Program's Impact with Rapid Polymerase Chain Reaction Methicillin- Resistant Staphylococcus aureus/S. aureus Blood Culture Test in Patients with S. aureus Bacteremia
    Bauer, Karri A.
    West, Jessica E.
    Balada-Llasat, Joan-Miquel
    Pancholi, Preeti
    Stevenson, Kurt B.
    Goff, Debra A.
    [J]. CLINICAL INFECTIOUS DISEASES, 2010, 51 (09) : 1074 - 1080
  • [4] Impact of mecA gene testing and intervention by infectious disease clinical pharmacists on time to optimal antimicrobial therapy for Staphylococcus aureus bacteremia at a University Hospital
    Carver, Peggy L.
    Lin, Shu-Wen
    DePestel, Daryl D.
    Newton, Duane W.
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2008, 46 (07) : 2381 - 2383
  • [5] Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: A meta-analysis
    DiazGranados, CA
    Zimmer, SM
    Klein, M
    Jernigan, JA
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 41 (03) : 327 - 333
  • [6] Peptide nucleic acid fluorescent in situ hybridization for hospital-acquired enterococcal bacteremia: Delivering earlier effective antimicrobial therapy
    Forrest, Graeme N.
    Roghmann, Mary-Claire
    Toombs, Latoya S.
    Johnson, Jennifer K.
    Weekes, Elizabeth
    Lincalis, Durry P.
    Venezia, Richard A.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (10) : 3558 - 3563
  • [7] Vancomycin-resistant enterococci: Mechanisms and clinical observations
    Gold, HS
    [J]. CLINICAL INFECTIOUS DISEASES, 2001, 33 (02) : 210 - 219
  • [8] Comparison of the Clinical Characteristics and Outcomes Associated with Vancomycin-Resistant Enterococcus faecalis and Vancomycin-Resistant E. faecium Bacteremia
    Hayakawa, Kayoko
    Marchaim, Dror
    Martin, Emily T.
    Tiwari, Namita
    Yousuf, Adnan
    Sunkara, Bharath
    Pulluru, Harish
    Kotra, Harikrishna
    Hasan, Asma
    Bheemreddy, Suchitha
    Sheth, Puja
    Lee, Dae-Won
    Kamatam, Srinivasa
    Bathina, Pradeep
    Nanjireddy, Priyanka
    Chalana, Indu K.
    Patel, Satyam
    Kumar, Sarwan
    Vahia, Amit
    Ku, Kimberly
    Yee, Victoria
    Swan, Jessie
    Pogue, Jason M.
    Lephart, Paul R.
    Rybak, Michael J.
    Kaye, Keith S.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (05) : 2452 - 2458
  • [9] Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America
    Mermel, Leonard A.
    Allon, Michael
    Bouza, Emilio
    Craven, Donald E.
    Flynn, Patricia
    O'Grady, Naomi P.
    Raad, Issam I.
    Rijnders, Bart J. A.
    Sherertz, Robert J.
    Warren, David K.
    [J]. CLINICAL INFECTIOUS DISEASES, 2009, 49 (01) : 1 - 45
  • [10] Nanosphere Inc, 2012, VER GRAM POS BLOOD C